Analysis Tools
mortality/aging
|
• no newborn homozygous pups are seen
|
|
Allele Symbol Allele Name Allele ID |
Apctm1Cip targeted mutation 1, Christine Perret MGI:3513416 |
||||||||||||||||||||||||||||||||
| Summary |
7 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• no newborn homozygous pups are seen
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• heterozygotes begin to die at 4 months of age with 50% dying by 6 months of age
|
|
• in situ carcinomas are seen in both the small and large intestines
• over 50% of lesions in mutants over 12 months of age are tubular adenomas harboring invasive carcinomas
|
|
• small and large adenomas are seen throughout the intestine
• the number of polyps is increased and the distribution of polyps shifted towards the ileum under specific pathogen-free conditions
|
|
• compared to ApcMin heterozygotes more lesions are see in the colon, however the overall number of lesions is the same in both lines
|
|
• 9% of heterozygotes developed mammary adenocanthomas
|
|
• first seen around 4 months of age, associated with decreased life span
|
|
• first seen around 4 months of age, associated with decreased life span
|
|
• rectal prolapse, associated with more severe polyposis in the colon, is seen as early as 4 months of age and is seen in 61% of surviving mutants by 6 months of age
• the prolapse is highly dysplatic and in 10% of these dysplatic areas adenocarcinoma is also seen
• fewer mutants raised in specific pathogen-free conditions developed rectal prolapse
|
|
• in situ carcinomas are seen in both the small and large intestines
• over 50% of lesions in mutants over 12 months of age are tubular adenomas harboring invasive carcinomas
|
|
• small and large adenomas are seen throughout the intestine
• the number of polyps is increased and the distribution of polyps shifted towards the ileum under specific pathogen-free conditions
|
|
• compared to ApcMin heterozygotes more lesions are see in the colon, however the overall number of lesions is the same in both lines
|
|
• 9% of heterozygotes developed mammary adenocanthomas
|
|
• 9% of heterozygotes developed mammary adenocanthomas
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| colorectal cancer | DOID:9256 |
OMIM:114500 |
J:94108 | |
| familial adenomatous polyposis | DOID:0050424 |
OMIM:PS175100 |
J:94108 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice exhibit a 1.4-fold increase in the number of adenomas compared to in Apctm1Cip heterozygotes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• some adenocarcinoma in situ in the intestines
|
|
• mice exhibit a 2.2-fold increase in the number of adenomas compared to in Apctm1Cip heterozygotes
|
|
• mice exhibit a 3-fold increase in the number of small polyps compared to in Apctm1Cip heterozygotes
|
|
• some adenocarcinoma in situ in the intestines
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• at 6-8 months of age, 83% of mice show symptoms of neoplasia (rectal bleeding, anemia, splenomegaly) and 1 or more macroadenomas in the intestinal tract relative to 56% in Apctm1Cip heterozygotes
• a greater % of mice develop 51 to 100 or over 100 polyps (all sizes) in the intestinal tract, and the average number of tumors per mouse is ~3-fold higher than that in Apctm1Cip heterozygotes
|
|
• at 6-8 months of age, 83% of mice show symptoms of neoplasia (rectal bleeding, anemia, splenomegaly) and 1 or more macroadenomas in the intestinal tract relative to 56% in Apctm1Cip heterozygotes
• a greater % of mice develop 51 to 100 or over 100 polyps (all sizes) in the intestinal tract, and the average number of tumors per mouse is ~3-fold higher than that in Apctm1Cip heterozygotes
|
|
• mice develop more tumors, esp. larger ones, in the intestinal tract; the average number of macroadenomas (>5 mm) per mouse is ~3-fold higher than that in Apctm1Cip heterozygotes
• however, no differences in tumor grade, aggressiveness or proliferation are observed
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 6 months after induction of colon tumors by AOM-DSS treatment, mice exhibit a significant decrease both in the number of neoplastic lesions/mouse and in total lesion area (mm2) relative to similarly treated mice heterozygous for Mki67em1Dfis and Apctm1Cip
|
|
• 6 months after AOM-DSS treatment, mice exhibit a significant decrease in total lesion area (mm2) relative to similarly treated mice heterozygous for Mki67em1Dfis and Apctm1Cip
|
|
• 6 months after induction of colon tumors by AOM-DSS treatment, mice exhibit a significant decrease both in the number of neoplastic lesions/mouse and in total lesion area (mm2) relative to similarly treated mice heterozygous for Mki67em1Dfis and Apctm1Cip
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/16/2024 MGI 6.23 |
|
|
|
||
